PharmaShots | Incisive News in 3 Shots

Subscribe Now

AbbVie

AbbVie to Acquire Cerevel Therapeutics for ~$8.7B

AbbVie to Acquire Cerevel Therapeutics for ~$8.7B

December 7, 2023

AbbVie Enters into a Collaboration Agreement with BigHat Biosciences to Discover and Develop Therapeutic Antibodies

AbbVie Enters into a Collaboration Agreement with BigHat Biosciences to Discover and Develop Therapeutic Antibodies

December 6, 2023

AbbVie to Acquire ImmunoGen for $10.1B

AbbVie to Acquire ImmunoGen for $10.1B

December 1, 2023

Abbvie Reports Positive Result for Telisotuzumab-Vedotin (Teliso-V) in P-II (LUMINOSITY) Study for the Treatment of NSCLC

Abbvie Reports Positive Result for Telisotuzumab-Vedotin (Teliso-V) in P-II (LUMINOSITY) Study for the Treatment of NSCLC

November 30, 2023

AbbVie Publishes Results for Ubrelvy (ubrogepant) in P-III Trial for Migraine in ‘The Lancet’

AbbVie Publishes Results for Ubrelvy (ubrogepant) in P-III Trial for Migraine in ‘The Lancet’

November 17, 2023

AbbVie Reports Head-To-Head P-III Study (SEQUENCE) of Skyrizi (risankizumab) for Crohn's Disease

AbbVie Reports Head-To-Head P-III Study (SEQUENCE) of Skyrizi (risankizumab) for Crohn's Disease

October 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us